Latest Posts › Patent-Eligible Subject Matter

Share:

USPTO to Release Revised Subject Matter Eligibility Guidance

In a conference call this morning, Drew Hirshfeld, U.S. Patent and Trademark Office Deputy Commissioner for Patent Examination Policy, announced that the USPTO would be releasing revised guidance on subject matter eligibility...more

12/15/2014 - Mayo v. Prometheus Myriad Patent-Eligible Subject Matter Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- The Coalition for 21st Century Medicine -- Part II

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

12/3/2014 - Coalition for 21st Century Medicine Draft Guidance Genetic Materials Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- The Coalition for 21st Century Medicine

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

12/2/2014 - Draft Guidance Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

BIO IPCC Panel Discusses Impact of Myriad-Mayo Guidance

Yesterday, we reported on a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsel's Committee fall conference, which took place earlier this week in Nashville, TN, in which the U.S. Patent and...more

11/14/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical USPTO

USPTO Provides Update on Status of Revised Myriad-Mayo Guidance

During a session of the Biotechnology Industry Organization (BIO) Intellectual Property Counsels Committee (IPCC) fall conference, which took place this week in Nashville, TN, the U.S. Patent and Trademark Office provided a...more

11/13/2014 - Biotechnology Genetic Materials Guidance Update Myriad-Mayo Patent-Eligible Subject Matter Patents USPTO

Examination of Myriad-Mayo Guidance Comments -- BIO Joint Comment

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

10/24/2014 - AMP v Myriad Biotechnology Draft Guidance Genetic Materials Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Manufacturers Public Comment Trade Associations USPTO

Sherry Knowles Addresses Real World Impact of Myriad-Mayo Guidance at BIO Symposium

Last month, at the Biotechnology Industry Organization (BIO) IP & Diagnostics Symposium in Alexandria, VA, Sherry Knowles of Knowles IP Strategies addressed the impact of the U.S. Patent and Trademark Office's Myriad-Mayo...more

10/16/2014 - Biotechnology Guidance Update Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Patents USPTO

USPTO Outlines Changes to Myriad-Mayo Guidance at BIO Symposium

Last Friday, at the Biotechnology Industry Organization (BIO) IP & Diagnostics Symposium in Alexandria, VA, the U.S. Patent and Trademark Office provided additional information regarding changes that the Office plans to make...more

10/1/2014 - AMP v Myriad Guidance Update Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Professional Conferences USPTO

Examination of Myriad-Mayo Guidance Comments -- International Bioindustry Associations

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/12/2014 - Biotechnology Mayo v. Prometheus Myriad Myriad-Mayo Patent Litigation Patent-Eligible Subject Matter Patents Pharmaceutical Pharmaceutical Patents Public Comment Rulemaking Process USPTO

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/6/2014 - ACLU Biotechnology Chemicals CLS Bank v Alice Corp Mayo v. Prometheus Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Public Comment Section 101 USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part IV

On May 9, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

7/10/2014 - AMP v Myriad Mayo v. Prometheus Patent-Eligible Subject Matter Patents SCOTUS USPTO

Docs @ BIO: USPTO Provides Update on Myriad-Mayo Guidance

At last week's BIO International Convention in San Diego, Andrew Hirshfeld, USPTO Deputy Commissioner for Patent Examination Policy, and June Cohan, a Legal Advisor with the USPTO's Office of Patent Legal Administration, took...more

7/2/2014 - DNA Genetic Materials Guidance Update Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Public Comment Section 101 Stem cells USPTO

USPTO Extends Deadline for Providing Feedback on Myriad-Mayo Guidance

As we reported earlier this week, the period for submitting written comments to the U.S. Patent and Trademark Office regarding the Office's Myriad-Mayo guidance memorandum has been extended to July 31, 2014. The Office...more

6/30/2014 - Memorandum of Guidance Myriad Myriad-Mayo Patent Trial and Appeal Board Patent-Eligible Subject Matter Patents USPTO

MBHB Snippets: Review of Developments in Intellectual Property Law - Volume 12, Issue 2 (Spring 2014)

In This Issue: - “Patent Trolls” in the Crosshairs – But How Will Patent Reform Legislation Impact the Rest of Us - USPTO Guidance Takes an Expansive View of Patent-Ineligible Subject Matter - Functional Claim...more

5/20/2014 - Data Protection Non-Practicing Entities Patent Exhaustion Patent Litigation Patent Reform Patent Trolls Patent-Eligible Subject Matter Trademarks USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part III

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/16/2014 - AMP v Myriad Mayo v. Prometheus Patent Applications Patent-Eligible Subject Matter Patents SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part II

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/15/2014 - Forum Myriad Patent Examinations Patent-Eligible Subject Matter Patents Public Comment SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part I

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/13/2014 - Guidance Update Myriad Patent Examinations Patent-Eligible Subject Matter Public Comment SCOTUS USPTO

USPTO Guidance Takes an Expansive View of Patent-Ineligible Subject Matter

On March 4, in a memorandum issued to the Patent Examining Corps by Deputy Commissioner for Patent Examination Policy Andrew Hirshfeld, the U.S. Patent and Trademark Office (“USPTO”) implemented a new procedure for...more

5/12/2014 - Patent Litigation Patent-Eligible Subject Matter Patents USPTO

In re Roslin Institute (Fed. Cir. 2014) - Dolly the Sheep Not Patent Eligible Subject Matter

Earlier today, the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board affirming the rejection of claims 155-159 and 164 of U.S. Application No. 09/225,233 as being directed to unpatentable subject...more

5/9/2014 - Genetic Materials Myriad Patent-Eligible Subject Matter Patents USPTO

USPTO Tries to Address Public Misunderstandings Regarding Myriad-Mayo Guidance

The U.S. Patent and Trademark Office spent the entire afternoon session of today's biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting focusing on the guidance memorandum for determining the subject...more

4/17/2014 - Biotechnology Myriad Patent-Eligible Subject Matter Pharmaceutical USPTO

USPTO Issues Guidance for Analyzing Subject Matter Eligibility of Claims Reciting Laws of Nature/Natural Principles, Natural...

Earlier today, in a memorandum issued to the Patent Examining Corps by Deputy Commissioner for Patent Examination Policy Andrew Hirshfeld, the U.S. Patent and Trademark Office implemented a new procedure for determining the...more

3/5/2014 - AMP v Myriad Mayo v. Prometheus Patent-Eligible Subject Matter SCOTUS USPTO

Top Stories of 2013: #4 to #6

Reflecting upon the events of the past twelve months, Patent Docs presents its seventh annual list of top biotech/pharma patent stories. For 2013, we identified fourteen stories that were covered on Patent Docs last year...more

1/3/2014 - Actavis Inc. America Invents Act Computer-Related Inventions FTC FTC v Actavis Patent Law Treaty Patent-Eligible Subject Matter Patents Reverse Payment Settlement Agreements SCOTUS USPTO

Sanofi-Aventis v. Pfizer Inc. (Fed. Cir. 2013)

Last week, in Sanofi-Aventis v. Pfizer Inc., the Federal Circuit affirmed an award of priority to Pfizer by the Board of Patent Appeals and Interferences in an interference involving the cDNA for the human interleukin-13...more

11/15/2013 - DNA Genetic Materials Human Genes Patent Litigation Patent-Eligible Subject Matter Patents Pfizer

23andMe Patent Creates Controversy

A patent issued to 23andMe, Inc. last month has created some controversy, and in response, the biotech company, based in Mountain View, California, has posted its side of the story on the 23andMe blog. The patent, U.S....more

10/9/2013 - 23andMe Biotechnology DNA Genetic Materials Human Genes Patent-Eligible Subject Matter Patents

Consumer Watchdog Argues That WARF Stem Cell Patent Is Invalid under § 101

Last month, Consumer Watchdog filed its opening brief in an appeal of a Board decision affirming the patentability of U.S. Patent No. 7,029,913, arguing that the claims of the '913 patent are invalid because they cover...more

8/2/2013 - AMP v Myriad DNA Inter Partes Review Proceedings Obviousness Patent-Eligible Subject Matter Patents Stem cells

32 Results
|
View per page
Page: of 2